FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090147133> ?p ?o ?g. }

• W3090147133 endingPage "e1920" @default.
• W3090147133 startingPage "e1909" @default.
• W3090147133 abstract "This is the first trial to explore the neoadjuvant therapy of pyrotinib in HER2-positive operable and locally advanced breast cancer, in combination with epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab. Results primarily showed that pyrotinib in combination with epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab was effective and safe in HER2-positive operable and locally advanced breast cancer. A subsequent randomized controlled trial is still warranted to confirm these results.The efficacy and safety of neoadjuvant therapy of pyrotinib, a new irreversible tyrosine kinase inhibitor (TKI), was first estimated in patients with HER2-positive breast cancer in this phase II study, in combination with trastuzumab and chemotherapy.Between February 19, 2019, and November 20, 2019, 20 female Chinese patients with stage I-III HER2-positive breast cancer were assigned to receive eight cycles of neoadjuvant pyrotinib (P) in combination with four cycles of epirubicin (E) and cyclophosphamide (C) followed by four cycles of docetaxel (T) and trastuzumab (H), once every 3 weeks, referred to as P + EC-TH.A total of 19 patients completed the therapy and final surgery. The total pathological complete response (tpCR) rate was 73.7% (95% confidence interval [CI], 48.8-90.9), and no recurrence or metastasis occurred during the short-term follow-up period. The objective response rate (ORR) was 100% (95% CI, 82.4-100). The most common adverse events (AEs) were diarrhea and leukopenia in 18 of 20 patients (90%), but no grade 5 AEs were reported.This study showed that in HER2-positive operable or locally advanced breast cancer, the tpCR rate of P + EC-TH neoadjuvant therapy was about twice as high as that of EC-TH neoadjuvant therapy reported in other trials, with tolerable side effects." @default.
• W3090147133 created "2020-10-08" @default.
• W3090147133 creator A5008154260 @default.
• W3090147133 creator A5008473333 @default.
• W3090147133 creator A5024125745 @default.
• W3090147133 creator A5024304452 @default.
• W3090147133 creator A5037504115 @default.
• W3090147133 creator A5037989560 @default.
• W3090147133 creator A5039541295 @default.
• W3090147133 creator A5047043019 @default.
• W3090147133 creator A5059430503 @default.
• W3090147133 creator A5059922337 @default.
• W3090147133 creator A5065408488 @default.
• W3090147133 creator A5069863669 @default.
• W3090147133 creator A5071975498 @default.
• W3090147133 creator A5076071644 @default.
• W3090147133 creator A5082895932 @default.
• W3090147133 date "2020-10-20" @default.
• W3090147133 modified "2023-10-16" @default.
• W3090147133 title "Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2-Positive Breast Cancer: A Phase II Clinical Trial" @default.
• W3090147133 cites W1990208211 @default.
• W3090147133 cites W1996778928 @default.
• W3090147133 cites W2037013151 @default.
• W3090147133 cites W2040935952 @default.
• W3090147133 cites W2048658106 @default.
• W3090147133 cites W2095865154 @default.
• W3090147133 cites W2096145980 @default.
• W3090147133 cites W2098775844 @default.
• W3090147133 cites W2101979288 @default.
• W3090147133 cites W2110444464 @default.
• W3090147133 cites W2111578514 @default.
• W3090147133 cites W2117984780 @default.
• W3090147133 cites W2120431466 @default.
• W3090147133 cites W2123591186 @default.
• W3090147133 cites W2125239609 @default.
• W3090147133 cites W2130034035 @default.
• W3090147133 cites W2133105825 @default.
• W3090147133 cites W2137228442 @default.
• W3090147133 cites W2146384083 @default.
• W3090147133 cites W2149908785 @default.
• W3090147133 cites W2151262170 @default.
• W3090147133 cites W2155560234 @default.
• W3090147133 cites W2159967578 @default.
• W3090147133 cites W2264000214 @default.
• W3090147133 cites W2301046115 @default.
• W3090147133 cites W2318605753 @default.
• W3090147133 cites W2399215084 @default.
• W3090147133 cites W2491147657 @default.
• W3090147133 cites W2588881638 @default.
• W3090147133 cites W2613098450 @default.
• W3090147133 cites W2768649895 @default.
• W3090147133 cites W2791139688 @default.
• W3090147133 cites W2806209829 @default.
• W3090147133 cites W2889646458 @default.
• W3090147133 cites W2899115689 @default.
• W3090147133 cites W2947964130 @default.
• W3090147133 cites W2969604985 @default.
• W3090147133 cites W2985724618 @default.
• W3090147133 cites W2994601580 @default.
• W3090147133 cites W4243460686 @default.
• W3090147133 doi "https://doi.org/10.1002/onco.13546" @default.
• W3090147133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8108050" @default.
• W3090147133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33000490" @default.
• W3090147133 hasPublicationYear "2020" @default.
• W3090147133 type Work @default.
• W3090147133 sameAs 3090147133 @default.
• W3090147133 citedByCount "17" @default.
• W3090147133 countsByYear W30901471332021 @default.
• W3090147133 countsByYear W30901471332022 @default.
• W3090147133 countsByYear W30901471332023 @default.
• W3090147133 crossrefType "journal-article" @default.
• W3090147133 hasAuthorship W3090147133A5008154260 @default.
• W3090147133 hasAuthorship W3090147133A5008473333 @default.
• W3090147133 hasAuthorship W3090147133A5024125745 @default.
• W3090147133 hasAuthorship W3090147133A5024304452 @default.
• W3090147133 hasAuthorship W3090147133A5037504115 @default.
• W3090147133 hasAuthorship W3090147133A5037989560 @default.
• W3090147133 hasAuthorship W3090147133A5039541295 @default.
• W3090147133 hasAuthorship W3090147133A5047043019 @default.
• W3090147133 hasAuthorship W3090147133A5059430503 @default.
• W3090147133 hasAuthorship W3090147133A5059922337 @default.
• W3090147133 hasAuthorship W3090147133A5065408488 @default.
• W3090147133 hasAuthorship W3090147133A5069863669 @default.
• W3090147133 hasAuthorship W3090147133A5071975498 @default.
• W3090147133 hasAuthorship W3090147133A5076071644 @default.
• W3090147133 hasAuthorship W3090147133A5082895932 @default.
• W3090147133 hasBestOaLocation W30901471331 @default.
• W3090147133 hasConcept C121608353 @default.
• W3090147133 hasConcept C126322002 @default.
• W3090147133 hasConcept C143998085 @default.
• W3090147133 hasConcept C2775930923 @default.
• W3090147133 hasConcept C2776694085 @default.
• W3090147133 hasConcept C2776755627 @default.
• W3090147133 hasConcept C2779786085 @default.
• W3090147133 hasConcept C2780835546 @default.
• W3090147133 hasConcept C2780873365 @default.
• W3090147133 hasConcept C2781190966 @default.
• W3090147133 hasConcept C530470458 @default.

• next